RecruitingNANCT04798131

Treat Refractory Auditory Hallucinations in Schizophrenia Patients With fMRI-guided Neurofeedback: a Randomized-controlled Trial

Sponsor: University Hospital, Lille

Trial Details

Condition	Schizophrenia, Hallucinations, Auditory, Hallucinations, Visual
Intervention	Active neurofeedback procedure; Sham neurofeedback procedure
Phase	NA
Status	Recruiting
Participants	84
Est. Completion	1 July 2026
Last Updated	18 May 2026

Primary Outcome

Change from baseline in the Auditory Hallucination Rating Scale (AHRS) measure of hallucinations severity

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Schizophrenia (according to the DSM-5 classification) * Frequent auditory hallucinations (SAPS item #1 ≥ 4) * Stable medication for at least 30 days * Absence of chronic neurological disorder (including seizure) * Able to provide free written consent to participate in the research Exclusion Criteria: * Pregnancy * Contraindication to MRI scan * Claustrophobia * No social insurance

Trial Sites

Countries

France

View Registry Entry

Related Analysis

INTRUDE Trial: fMRI-Guided Neurofeedback vs Sham for Treatment-Resistant Auditory Hallucinations in Schizophrenia

The INTRUDE trial investigates fMRI-guided neurofeedback for treatment-resistant auditory hallucinations in schizophrenia. This innovative approach uses real-time brain imaging to train patients to control hallucination-related neural activity patterns.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service